Review maps natural-product pathways for colitis research
Bottom line
Recent research is sharpening the case for natural products as adjunct tools in colitis care, but the new paper is more roadmap than practice-changing trial. In a review published May 29, 2026, in Veterinary Sciences, researchers from Yangzhou University summarized evidence on flavonoids, polyphenols, alkaloids, terpenoids, saponins, polysaccharides, plant extracts, and traditional herbal formulas for colitis, focusing on how these compounds may reduce inflammatory signaling, oxidative stress, epithelial barrier injury, immune dysregulation, dysbiosis, and programmed cell death. The authors argue these mechanisms could have translational relevance not just for human ulcerative colitis models, but also for companion animals, horses, and production species with colitis or colitis-like intestinal inflammation. (mdpi.com)
Why it matters: For veterinary professionals, the paper reflects a broader shift toward microbiota-directed, diet-linked, and adjunctive strategies in chronic intestinal disease, especially as long-term drug costs, relapse, and antimicrobial stewardship remain ongoing concerns. But it's important to keep the evidence hierarchy in view: this is a narrative review built largely on preclinical and experimental colitis literature, not a clinical guideline for dogs or cats. Current veterinary guidance for chronic inflammatory enteropathy still centers on structured diagnosis, diet, and evidence-based medical therapy, while interest in microbiome and nutraceutical approaches continues to grow. (ebvminpractice.org)
What to watch: The next step is whether specific natural compounds or formulations move from rodent and mechanistic studies into controlled veterinary clinical trials with standardized products, dosing, and outcomes. (mdpi.com)
Key facts
- Article type
- Narrative review
- Publication date
- May 29, 2026
- Journal
- Veterinary Sciences
- Institution
- Yangzhou University
- Focus
- Natural products as adjuncts for colitis
- Compounds reviewed
- Flavonoids, polyphenols, alkaloids, terpenoids, saponins, polysaccharides, plant extracts, and traditional herbal formulas
- Main mechanisms
- Inflammatory signaling, oxidative stress, epithelial barrier injury, immune dysregulation, dysbiosis, and programmed cell death
- Evidence base
- Mostly preclinical and experimental colitis literature, not a clinical guideline for dogs or cats
A newly published review in Veterinary Sciences puts natural products back into focus as possible adjuncts for colitis, laying out how plant- and food-derived compounds may act on several of the disease's core pathways at once. Published May 29, 2026, the paper comes from investigators at Yangzhou University and surveys a wide range of candidates, from flavonoids and polyphenols to polysaccharides, terpenoids, and herbal formulas. Rather than announcing a new treatment, the article synthesizes where the science is moving and where translational gaps remain. (mdpi.com)
That timing matters because colitis and chronic inflammatory enteropathies remain frustrating conditions across species. In dogs and cats, chronic gastrointestinal inflammation can be difficult to classify and manage, with overlap among food-responsive disease, immune-mediated inflammation, dysbiosis-associated disease, and more localized colitis syndromes. The WSAVA gastrointestinal guidelines were developed in part to standardize histopathology and improve comparability across studies, while newer ACVIM-endorsed guidance emphasizes a stepwise diagnostic and treatment approach for canine chronic inflammatory enteropathy. (wsava.org)
The review's core message is that natural products may be attractive because they are multitarget rather than single-pathway interventions. The authors group the evidence around several recurring mechanisms: suppression of inflammatory signaling, reduction of oxidative stress, restoration of mucosal barrier integrity, modulation of immune responses, reshaping of gut microbiota and metabolites, and regulation of programmed cell death. They also highlight formulation challenges, noting that poor stability, low bioavailability, and limited colonic enrichment have pushed delivery systems such as liposomes, hydrogels, nanocarriers, and colon-targeted release platforms into the spotlight. (mdpi.com)
For veterinary readers, one of the more useful parts of the paper is its explicit comparative framing. The authors note that colitis-related disorders affect companion animals, horses, and food-producing species, contributing to diarrhea, impaired barrier function, welfare issues, reduced performance, treatment costs, and antimicrobial-use concerns. That fits with broader veterinary literature showing that dysbiosis and intestinal inflammation are linked across domestic species, and that canine inflammatory bowel disease in particular shares several microbiome features with human disease. (mdpi.com)
Outside this review, the wider field is also moving toward microbiome-aware management, but with caution. An ACVIM-endorsed 2026 statement on canine chronic inflammatory enteropathy, as summarized by dvm360, highlighted the central role of diet and the possible value of microbiome-directed interventions, while also noting that evidence for many products remains limited and that most probiotic products don't meet a high evidentiary bar. Meanwhile, the Merck Veterinary Manual continues to frame colitis treatment around identifying cause, dietary management, and supportive measures such as fiber, underscoring that adjunctive nutritional strategies are not new, but product-specific claims still need proof. (dvm360.com)
Why it matters: This review is best read as a signal of research direction, not a reason to overhaul protocols. For clinicians, the practical takeaway is that natural products are being studied in increasingly mechanistic ways, especially around barrier protection, redox signaling, and microbiome modulation, all of which are highly relevant to chronic enteropathies in dogs and cats. But the translational hurdles are substantial: many data come from chemically induced rodent colitis models, natural-product preparations are heterogeneous, dosing is inconsistent, and veterinary species-specific efficacy and safety data are still thin. (mdpi.com)
That leaves veterinary teams in a familiar position. Pet parents are likely to ask about "natural" options for chronic diarrhea, colitis, or IBD, especially when relapses, steroid adverse effects, or cost are concerns. This paper gives clinicians a clearer framework for those conversations: some compounds have plausible mechanisms and growing preclinical support, but evidence-based care still depends on diagnosis, diet trials, targeted therapy, and careful follow-up rather than broad extrapolation from bench science. (mdpi.com)
What to watch: Expect the most meaningful next developments to come from standardized veterinary trials of specific compounds or combination products, especially those paired with delivery technologies or microbiome-focused endpoints, rather than from additional broad reviews alone. (mdpi.com)